Molecular Mechanisms of Tumor Angiogenesis

Genes and Cancer

Volumn 2, Issue 12, 2011, Pages 1085-1096

  Ziyad, Safiyyah ^a   Iruela Arispe, M Luisa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

angiopoietins; Delta; endothelial cells; Eph; Ephrin; Jagged; neovascularization; Notch; Robo; Slit; Tie; tumor angiogenesis; VEGF; VEGFR

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; EPHRIN; NEUROPILIN 1; NEUROPILIN 2; NOTCH RECEPTOR; ROUNDABOUT RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CELL FATE; ENDOTHELIUM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR BLOOD FLOW; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; TUMOR VASCULARIZATION;

EID: 84868615586     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911432334     Document Type: Article

References (141)

1. Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation.Cell. 2011;144:646-74.
2. Chaffer CL,Weinberg RA.A perspective on cancer cell metastasis.Science. 2011;331:1559-64.
3. Egeblad M,Nakasone ES,Werb Z.Tumors as organs: complex tissues that interface with the entire organism.Dev Cell. 2010;18:884-901.
4. Bissell MJ,Hines WC.Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression.Nat Med. 2011;17:320-9.
5. Chouaib S,Kieda C,Benlalam H,Noman MZ,Mami-Chouaib F,Ruegg C.Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells.Crit Rev Immunol. 2010;30:529-45.
6. Schreiber RD,Old LJ,Smyth MJ.Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.Science. 2011;331:1565-70.
7. Baglole CJ,Ray DM,Bernstein SH, et al.More than structural cells, fibroblasts create and orchestrate the tumor microenvironment.Immunol Invest. 2006;35:297-325.
8. Xing F,Saidou J,Watabe K.Cancer associated fibroblasts (CAFs) in tumor microenvironment.Front Biosci. 2010;15:166-79.
9. Kessenbrock K,Plaks V,Werb Z.Matrix metalloproteinases: regulators of the tumor microenvironment.Cell. 2010;141:52-67.
10. Dvorak HF.Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.N Engl J Med. 1986;315:1650-9.
11. Demaria S,Pikarsky E,Karin M, et al.Cancer and inflammation: promise for biologic therapy.J Immunother. 2010;33:335-51.
12. Hanahan D,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.Cell. 1996;86:353-64.
13. Leenders WP,Kusters B,de Waal RM.Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis.Endothelium. 2002;9:83-7.
14. Hillen F,Griffioen A.Tumour vascularization: sprouting angiogenesis and beyond.Cancer Metastasis Rev. 2007;26:489-502.
15. Zhao C,Yang H,Shi H, et al.Distinct contributions of angiogenesis and vascular co-option during the initiation of primary microtumors and micrometastases.Carcinogenesis. 2011;32:1143-50.
16. Nagy JA,Chang S-H,Shih S-C,Dvorak AM,Dvorak HF.Heterogeneity of the tumor vasculature.Semin Thromb Hemost. 2010;36:321-31.
17. Chaplin DJ,Olive PL,Durand RE.Intermittent blood flow in a murine tumor: radiobiological effects.Cancer Res. 1987;47:597-601.
18. Nagy JA,Chang SH,Dvorak AM,Dvorak HF.Why are tumour blood vessels abnormal and why is it important to know?.Br J Cancer. 2009;100:865-9.
19. Nagy J,Benjamin L,Zeng H,Dvorak A,Dvorak H.Vascular permeability, vascular hyperpermeability and angiogenesis.Angiogenesis. 2008;11:109-19.
20. Fukumura DAI,Duda DG,Munn LL,Jain RK.Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models.Microcirculation. 2010;17:206-25.
21. Harris AL.Hypoxia: a key regulatory factor in tumour growth.Nat Rev Cancer. 2002;2:38-47.
22. Xu L,Fukumura D,Jain RK.Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF.J Biol Chem. 2002;277:11368-74.
23. Fukumura D,Jain RK.Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize.J Cell Biochem. 2007;101:937-49.
24. Boucher Y,Brekken C,Netti PA,Baxter LT,Jain RK.Intratumoral infusion of fluid: estimation of hydraulic conductivity and implications for the delivery of therapeutic agents.Br J Cancer. 1998;78:1442-8.
25. Boucher Y,Salehi H,Witwer B,Harsh GRT,Jain RK.Interstitial fluid pressure in intracranial tumours in patients and in rodents.Br J Cancer. 1997;75:829-36.
26. Yuan F,Salehi HA,Boucher Y,Vasthare US,Tuma RF,Jain RK.Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows.Cancer Res. 1994;54:4564-8.
27. Tong RT,Boucher Y,Kozin SV,Winkler F,Hicklin DJ,Jain RK.Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors.Cancer Res. 2004;64:3731-6.
28. Winkler F,Kozin SV,Tong RT, et al.Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.Cancer Cell. 2004;6:553-63.
29. Willett CG,Boucher Y,Di Tomaso E, et al.Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.Nat Med. 2004;10:145-7.
30. Weick A,Augustin HG.Double attack on tumors by targeting with guidance molecules.Arterioscler Thromb Vasc Biol. 2011;31:721-2.
31. Adams RH,Eichmann A.Axon guidance molecules in vascular patterning.Cold Spring Harb Perspect Biol. 2010;2:.
32. Casazza A,Fu X,Johansson I, et al.Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models.Arterioscler Thromb Vasc Biol. 2011;31:741-9.
33. Warren CM,Iruela-Arispe ML.Signaling circuitry in vascular morphogenesis.Curr Opin Hematol. 2010;17:213-8.
34. Arroyo AG,Iruela-Arispe ML.Extracellular matrix, inflammation, and the angiogenic response.Cardiovasc Res. 2010;86:226-35.
35. Carmeliet P,Jain RK.Angiogenesis in cancer and other diseases.Nature. 2000;407:249-57.
36. Carmeliet P,Jain RK.Molecular mechanisms and clinical applications of angiogenesis.Nature. 2011;473:298-307.
37. Ferrara N,Mass RD,Campa C,Kim R.Targeting VEGF-A to treat cancer and age-related macular degeneration.Annu Rev Med. 2007;58:491-504.
38. Germain S,Monnot C,Muller L,Eichmann A.Hypoxia-driven angiogenesis: role of tip cells and extracellular matrix scaffolding.Curr Opin Hematol. 2010;17:245-51.
39. Grunewald FS,Prota AE,Giese A,Ballmer-Hofer K.Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling.Biochim Biophys Acta. 2010;1804:567-80.
40. Ferrara N.Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action.Mol Biol Cell. 2010;21:687-90.
41. Lee S,Jilani SM,Nikolova GV,Carpizo D,Iruela-Arispe ML.Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors.J Cell Biol. 2005;169:681-91.
42. Chen TT,Luque A,Lee S,Anderson SM,Segura T,Iruela-Arispe ML.Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells.J Cell Biol. 2010;188:595-609.
43. Evans IM,Yamaji M,Britton G, et al.Neuropilin-1 signaling through p130Cas tyrosine phosphorylation is essential for growth factor-dependent migration of glioma and endothelial cells.Mol Cell Biol. 2011;31:1174-85.
44. Ruhrberg C,Gerhardt H,Golding M, et al.Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis.Genes Dev. 2002;16:2684-98.
45. Soker S,Fidder H,Neufeld G,Klagsbrun M.Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain.J Biol Chem. 1996;271:5761-7.
46. Soker S,Takashima S,Miao HQ,Neufeld G,Klagsbrun M.Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.Cell. 1998;92:735-45.
47. Pan Q,Chathery Y,Wu Y, et al.Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting.J Biol Chem. 2007;282:24049-56.
48. Kitsukawa T,Shimizu M,Sanbo M, et al.Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice.Neuron. 1997;19:995-1005.
49. Zachary IC,Frankel P,Evans IM,Pellet-Many C.The role of neuropilins in cell signalling.Biochem Soc Trans. 2009;37:1171-8.
50. Pellet-Many C,Frankel P,Jia H,Zachary I.Neuropilins: structure, function and role in disease.Biochem J. 2008;411:211-26.
51. Mamluk R,Gechtman Z,Kutcher ME,Gasiunas N,Gallagher J,Klagsbrun M.Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain.J Biol Chem. 2002;277:24818-25.
52. Gu C,Limberg BJ,Whitaker GB, et al.Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem; 2002; 2002. 18069.
53. Soker S,Miao HQ,Nomi M,Takashima S,Klagsbrun M.VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding.J Cell Biochem. 2002;85:357-68.
54. Wang L,Zeng H,Wang P,Soker S,Mukhopadhyay D.Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration.J Biol Chem. 2003;278:48848-60.
55. Cai H,Reed RR.Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1.J Neurosci. 1999;19:6519-27.
56. Wang L,Mukhopadhyay D,Xu X.C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis.FASEB J. 2006;20:1513-5.
57. Evans IM,Yamaji M,Britton G, et al.Neuropilin-1 signaling through p130Cas tyrosine phosphorylation is essential for growth factor-dependent migration of glioma and endothelial cells.Mol Cell Biol. 2011;31:1174-85.
58. Herzog B,Pellet-Many C,Britton G,Hartzoulakis B,Zachary IC.VEGF binding to neuropilin-1 (NRP1) is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2 and signalling via FAK Tyr407 phosphorylation.Mol Biol Cell. 2011;22:2766-76.
59. Jarvis A,Allerston CK,Jia H, et al.Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction.J Med Chem. 2010;53:2215-26.
60. Pan Q,Chanthery Y,Liang WC, et al.Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.Cancer Cell. 2007;11:53-67.
61. Ghabrial AS,Krasnow MA.Social interactions among epithelial cells during tracheal branching morphogenesis.Nature. 2006;441:746-9.
62. Louvi A,Artavanis-Tsakonas S.Notch signalling in vertebrate neural development.Nat Rev Neurosci. 2006;7:93-102.
63. Carmeliet P,Tessier-Lavigne M.Common mechanisms of nerve and blood vessel wiring.Nature. 2005;436:193-200.
64. Uv A,Cantera R,Samakovlis C.Drosophila tracheal morphogenesis: intricate cellular solutions to basic plumbing problems.Trends Cell Biol. 2003;13:301-9.
65. Kopan R,Ilagan MXG.The canonical Notch signaling pathway: unfolding the activation mechanism.Cell. 2009;137:216-33.
66. Jakobsson L,Bentley K,Gerhardt H.VEGFRs and Notch: a dynamic collaboration in vascular patterning.Biochem Soc Trans. 2009;37:1233-6.
67. Gerhardt H,Golding M,Fruttiger M, et al.VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.J Cell Biol. 2003;161:1163-77.
68. Liu Z-J,Shirakawa T,Li Y, et al.Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis.Mol Cell Biol. 2003;23:14-25.
69. Lobov IB,Renard RA,Papadopoulos N, et al.Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting.Proc Natl Acad Sci U S A. 2007;104:3219-24.
70. Hellstrom M,Phng L-K,Hofmann JJ, et al.Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.Nature. 2007;445:776-80.
71. Ridgway J,Zhang G,Wu Y, et al.Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.Nature. 2006;444:1083-7.
72. Noguera-Troise I,Daly C,Papadopoulos NJ, et al.Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.Nature. 2006;444:1032-7.
73. Thurston G,Noguera-Troise I,Yancopoulos GD.The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth.Nat Rev Cancer. 2007;7:327-31.
74. Gaengel K,Genove G,Armulik A,Betsholtz C.Endothelial-mural cell signaling in vascular development and angiogenesis.Arterioscler Thromb Vasc Biol. 2009;29:630-8.
75. Iivanainen E,Nelimarkka L,Elenius V, et al.Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor.FASEB J. 2003;17:1609-21.
76. Kobayashi H,DeBusk LM,Babichev YO,Dumont DJ,Lin PC.Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment.Blood. 2006;108:1260-6.
77. Lindahl P,Johansson BR,Leveen P,Betsholtz C.Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.Science. 1997;277:242-5.
78. Zhang J,Fukuhara S,Sako K, et al.Angiopoietin-1/Tie2 signal augments basal Notch signal controlling vascular quiescence by inducing delta-like 4 expression through AKT-mediated activation of beta-catenin.J Biol Chem. 2011;286:8055-66.
79. Abramsson A,Lindblom P,Betsholtz C.Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors.J Clin Invest. 2003;112:1142-51.
80. Hellstrom M,Kalen M,Lindahl P,Abramsson A,Betsholtz C.Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse.Development. 1999;126:3047-55.
81. Korhonen J,Polvi A,Partanen J,Alitalo K.The mouse tie receptor tyrosine kinase gene: expression during embryonic angiogenesis.Oncogene. 1994;9:395-403.
82. De Palma M,Venneri MA,Galli R, et al.Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.Cancer Cell. 2005;8:211-26.
83. Dumont DJ,Yamaguchi TP,Conlon RA,Rossant J,Breitman ML.tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors.Oncogene. 1992;7:1471-80.
84. Fiedler U,Scharpfenecker M,Koidl S, et al.The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies.Blood. 2004;103:4150-6.
85. Augustin HG,Young Koh G,Thurston G,Alitalo K.Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.Nat Rev Mol Cell Biol. 2009;10:165-77.
86. Fukuhara S,Sako K,Minami T, et al.Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1.Nat Cell Biol. 2008;10:513-26.
87. Saharinen P,Eklund L,Miettinen J, et al.Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts.Nat Cell Biol. 2008;10:527-37.
88. Maisonpierre PC,Suri C,Jones PF, et al.Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.Science. 1997;277:55-60.
89. Scharpfenecker M,Fiedler U,Reiss Y,Augustin HG.The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism.J Cell Sci. 2005;118:771-80.
90. Daly C,Pasnikowski E,Burova E, et al.Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells.Proc Natl Acad Sci U S A. 2006;103:15491-6.
91. Marron MB,Singh H,Tahir TA, et al.Regulated proteolytic processing of Tie1 modulates ligand responsiveness of the receptor-tyrosine kinase Tie2.J Biol Chem. 2007;282:30509-17.
92. Yuan HT,Venkatesha S,Chan B, et al.Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival.FASEB J. 2007;21:3171-83.
93. Martin V,Liu D,Fueyo J,Gomez-Manzano C.Tie2: a journey from normal angiogenesis to cancer and beyond.Histol Histopathol. 2008;23:773-80.
94. Lewis CE,Ferrara N.Multiple effects of angiopoietin-2 blockade on tumors.Cancer Cell. 2011;19:431-3.
95. Schubert SY,Benarroch A,Monter-Solans J,Edelman ER.Primary monocytes regulate endothelial cell survival through secretion of angiopoietin-1 and activation of endothelial Tie2.Arterioscler Thromb Vasc Biol. 2011;31:870-5.
96. Huang H,Lai J-Y,Do J, et al.Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.Clin Cancer Res. 2011;17:1001-11.
97. Mazzieri R,Pucci F,Moi D, et al.Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.Cancer Cell. 2011;19:512-26.
98. Huang H,Bhat A,Woodnutt G,Lappe R.Targeting the ANGPT-TIE2 pathway in malignancy.Nat Rev Cancer. 2010;10:575-85.
99. Bashaw GJ,Klein R.Signaling from axon guidance receptors.Cold Spring Harb Perspect Biol. 2010;2:.
100. Mosch B,Reissenweber B,Neuber C,Pietzsch J.Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis.J Oncol. 2010;2010:135285.
101. Heroult M,Schaffner F,Augustin HG.Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression.Exp Cell Res. 2006;312:642-50.
102. Kuijper S,Turner CJ,Adams RH.Regulation of angiogenesis by Eph-ephrin interactions.Trends Cardiovasc Med. 2007;17:145-51.
103. Gale NW,Baluk P,Pan L, et al.Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells.Dev Biol. 2001;230:151-60.
104. Shin D,Garcia-Cardena G,Hayashi S-I, et al.Expression of EphrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization.Dev Biol. 2001;230:139-50.
105. Adams RH,Wilkinson GA,Weiss C, et al.Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis.Genes Dev. 1999;13:295-306.
106. Gerety SS,Wang HU,Chen ZF,Anderson DJ.Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development.Mol Cell. 1999;4:403-14.
107. Wang HU,Chen ZF,Anderson DJ.Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4.Cell. 1998;93:741-53.
108. Korff T,Dandekar G,Pfaff D, et al.Endothelial ephrinB2 is controlled by microenvironmental determinants and associates context-dependently with CD31.Arterioscler Thromb Vasc Biol. 2006;26:468-74.
109. Le Noble F,Moyon D,Pardanaud L, et al.Flow regulates arterial-venous differentiation in the chick embryo yolk sac.Development. 2004;131:361-75.
110. Fuller T,Korff T,Kilian A,Dandekar G,Augustin HG.Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells.J Cell Sci. 2003;116:2461-70.
111. Kim YH,Hu H,Guevara-Gallardo S,Lam MT,Fong SY,Wang RA.Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis.Development. 2008;135:3755-64.
112. Foo SS,Turner CJ,Adams S, et al.Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly.Cell. 2006;124:161-73.
113. Salvucci O,Maric D,Economopoulou M, et al.EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures.Blood. 2009;114:1707-16.
114. Cheng N,Brantley DM,Liu H, et al.Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.Mol Cancer Res. 2002;1:2-11.
115. McBride JL,Ruiz JC.Ephrin-A1 is expressed at sites of vascular development in the mouse.Mech Dev. 1998;77:201-4.
116. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer; 2010:165-80.
117. Ogawa K,Pasqualini R,Lindberg RA,Kain R,Freeman AL,Pasquale EB.The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.Oncogene. 2000;19:6043-52.
118. Walker-Daniels J,Hess AR,Hendrix MJ,Kinch MS.Differential regulation of EphA2 in normal and malignant cells.Am J Pathol. 2003;162:1037-42.
119. Vihanto MM,Plock J,Erni D,Frey BM,Frey FJ,Huynh-Do U.Hypoxia up-regulates expression of Eph receptors and ephrins in mouse skin.FASEB J. 2005;19:1689-91.
120. Fang WB,Brantley-Sieders DM,Parker MA,Reith AD,Chen J.A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.Oncogene. 2005;24:7859-68.
121. Brantley-Sieders DM,Fang WB,Hicks DJ,Zhuang G,Shyr Y,Chen J.Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.FASEB J. 2005;19:1884-6.
122. Brantley DM,Cheng N,Thompson EJ, et al.Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.Oncogene. 2002;21:7011-26.
123. Dobrzanski P,Hunter K,Jones-Bolin S, et al.Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.Cancer Res. 2004;64:910-9.
124. Cheng N,Brantley D,Fang WB, et al.Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.Neoplasia. 2003;5:445-56.
125. Sawamiphak S,Seidel S,Essmann CL, et al.Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis.Nature. 2010;465:487-91.
126. Wang Y,Nakayama M,Pitulescu ME, et al.Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.Nature. 2010;465:483-6.
127. Kertesz N,Krasnoperov V,Reddy R, et al.The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.Blood. 2006;107:2330-8.
128. Martiny-Baron G,Korff T,Schaffner F, et al.Inhibition of tumor growth and angiogenesis by soluble EphB4.Neoplasia. 2004;6:248-57.
129. Djokovic D,Trindade A,Gigante J, et al.Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.BMC Cancer. 2010;10:641.
130. Liao WX,Wing DA,Geng JG,Chen DB.Perspectives of SLIT/ROBO signaling in placental angiogenesis.Histol Histopathol. 2010;25:1181-90.
131. Wang B,Xiao Y,Ding B-B, et al.Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity.Cancer Cell. 2003;4:19-29.
132. Huminiecki L,Gorn M,Suchting S,Poulsom R,Bicknell R.Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis.Genomics. 2002;79:547-52.
133. Suchting S,Heal P,Tahtis K,Stewart LM,Bicknell R.Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration.FASEB J. 2005;19:121-3.
134. Fukuhara N,Howitt JA,Hussain SA,Hohenester E.Structural and functional analysis of slit and heparin binding to immunoglobulin-like domains 1 and 2 of Drosophila Robo.J Biol Chem. 2008;283:16226-34.
135. Legg JA,Herbert JM,Clissold P,Bicknell R.Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration.Angiogenesis. 2008;11:13-21.
136. Sheldon H,Andre M,Legg JA, et al.Active involvement of Robo1 and Robo4 in filopodia formation and endothelial cell motility mediated via WASP and other actin nucleation-promoting factors.FASEB J. 2009;23:513-22.
137. Jones CA,London NR,Chen H, et al.Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability.Nat Med. 2008;14:448-53.
138. Jones CA,Nishiya N,London NR, et al.Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity.Nat Cell Biol. 2009;11:1325-31.
139. Marlow R,Binnewies M,Sorensen LK, et al.Vascular Robo4 restricts proangiogenic VEGF signaling in breast.Proc Natl Acad Sci U S A. 2010;107:10520-5.
140. Dunaway CM,Hwang Y,Lindsley CW, et al.Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis.Mol Cell Biol. 2011;31:404-16.
141. Koch AW,Mathivet T,Larrivee B, et al.Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B.Dev Cell. 2011;20:33-46.